MentionFox
Home › Executive changes › Foghorn Therapeutics Inc.
Leadership changes · FHTX · SEC Form 8-K, Item 5.02

Leadership changes at Foghorn Therapeutics Inc. (2026)

Before you join, sell to or invest in Foghorn Therapeutics Inc.

MentionFox check on Foghorn Therapeutics Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/foghorn-therapeutics

  • Note: Layoff plan disclosed Oct 2026 (about 65 employees) (filing)

Check Foghorn Therapeutics Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Foghorn Therapeutics Inc.?

Who joined and who left Foghorn Therapeutics Inc. (FHTX)? 2 appointments reported on 2026-02-23, each cited to the company's own filing.

Ryan D. Maynard was named Chief Financial Officer of Foghorn Therapeutics Inc. As of November 14, 2026, Foghorn Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 23, 2026, naming 2 appointments (Form 8-K, February 23, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Deerfield Mgmt, L.P. also filed stake reports on 19 other companies ↓

Sell to companies like Foghorn Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes2
In (appointed)2
Latest filing2026-02-23

Foghorn Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-23. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Foghorn Therapeutics Inc. files it.

Layoffs on record: about 65 jobs, latest 2026-10-01 (layoff filings and notices).

Also on the record for Foghorn Therapeutics Inc.

DateRecordFigureOur pageSource
October 5, 2026Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL14.3% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL9.99% of the class5%+ stakesSource
May 14, 2026Stake report, Schedule 13G/A, by Deerfield Mgmt, L.P.8.64% of the class5%+ stakesSource
May 6, 2026Stake report, Schedule 13G/A, by FMR LLC11.6% of the class5%+ stakesSource
January 13, 2026Stake report, Schedule 13D/A, by Flagship Ventures Fund V, L.P.27.2% of the class5%+ stakesSource

Selling to them or working with them? See who runs Foghorn Therapeutics Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Foghorn Therapeutics Inc. and the records around it.

Foghorn Therapeutics Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Foghorn Therapeutics Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Foghorn Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Foghorn Therapeutics Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    7 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-02-23InChief Financial Officer8-K, 2026-02-23
2026-02-23In8-K, 2026-02-23

Who leads Foghorn Therapeutics Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Foghorn Therapeutics Inc.?

New leaders reset buying decisions — get the Full Report on Foghorn Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Foghorn Therapeutics Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Financial Officer at Foghorn Therapeutics Inc., with the record behind each one.

Find candidates like Chief Financial Officer at Foghorn Therapeutics Inc.

Every change, in the filing's words

Filed 2026-02-23 · 8-K

Appointed: Ryan D. Maynard, Chief Financial Officer

On February 23, 2026, Foghorn Therapeutics Inc. (the "Company") announced that Ryan D. Maynard had been appointed to serve as the Company's Chief Financial Officer, effective immediately.

Appointed: Ryan D. Maynard

In connection with his appointment, Mr. Maynard will serve as the Company's principal financial officer and principal accounting officer.

Also stated in this filing

  • Mr. Maynard, age 56, previously served as Chief Financial Officer of Cara Therapeutics, Inc., a publicly-traded commercial-stage biopharmaceutical company, from September 2022 to 2025.
  • Prior to that role he served as the Chief Financial Officer of Paulus Holdings Ltd. d/b/a LetsGetChecked, a global healthcare solutions company, from October 2019 to March 2022, as the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company, from February 2018 to June 2019, and as Chief Financial Officer of Rigel Pharmaceuticals, Inc, a public biotechnology company, from 2001 to 2017.
  • Mr. Maynard started his career at Ernst and Young LLP., where he earned his CPA.
  • He holds a B.S. in Commerce-Accounting from Santa Clara University.
  • In connection with his appointment as Chief Financial Officer, Mr. Maynard and the Company entered into a letter agreement that sets forth the terms and conditions of his employment (the "Employment Agreement").
  • The Employment Agreement provides for (i) an annual base salary of $510,000, (ii) eligibility to receive an annual performance bonus targeted at 40% of his annual base salary, (iii) a signing bonus of $90,000, (iv) an option award granted under the Company's 2020 Equity Incentive Plan to purchase 400,000 shares of common stock of the Company, to be granted on or after February 23, 2026.

Tools for this story

Each opens in a new tab, filled in for Foghorn Therapeutics Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/foghorn-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Foghorn Therapeutics Inc. names Ryan D. Maynard CFO (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/foghorn-therapeutics